[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

March 2018, Vol 4, No. 3, Pages 275-431

Original Investigation

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):302-308. doi:10.1001/jamaoncol.2017.4612

This randomized clinical trial determines whether nab-paclitaxel improves the outcomes of early and locally advanced ERBB2/HER2-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.

Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome

Abstract Full Text
free access has audio
JAMA Oncol. 2018;4(3):309-315. doi:10.1001/jamaoncol.2017.4420

This cohort analysis examined 3-year recurrence-free survival in patients with varying levels of preoperative and postoperative carcinoembryonic antigen.

Trends in Cancer Survival by Health Insurance Status in California From 1997 to 2014

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):317-323. doi:10.1001/jamaoncol.2017.3846

This population-based study of data from the California Cancer Registry examines trends in cancer survival by health insurance status from January 1997 to December 2014.

Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):326-332. doi:10.1001/jamaoncol.2017.4445

This study examined the American Society of Clinical Oncology’s value framework for awarding bonus points to immuno-oncology agents for durable long-term survival.

Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):335-341. doi:10.1001/jamaoncol.2017.4510

This population-based, case-control study examines the relative and absolute risks of breast anaplastic large-cell lymphoma in women with breast implants.

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):343-350. doi:10.1001/jamaoncol.2017.4600

This systematic review and meta-analysis reviews phase 3 randomized clinical trials of high-dose therapy followed by autologous stem cell transplant in patients with multiple myeloma.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):351-357. doi:10.1001/jamaoncol.2017.4771

This cohort study investigates whether the pretreatment derived neutrophils/(leukocytes minus neutrophils) ratio and lactate dehydrogenase level are associated with resistance to immunotherapy in patients with advanced non–small cell lung cancer.

Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):358-365. doi:10.1001/jamaoncol.2017.4777

This nested case-control study uses 2 large US cohorts to examine the association of the oral microbiome with subsequent risk of head and neck squamous cell cancer.

Association of Dietary Inflammatory Potential With Colorectal Cancer Risk in Men and Women

Abstract Full Text
free access has audio
JAMA Oncol. 2018;4(3):366-373. doi:10.1001/jamaoncol.2017.4844

This cohort study followed participants for 26 years to determine whether proinflammatory diets are associated with increased colorectal cancer risk.

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(3):e174519. doi:10.1001/jamaoncol.2017.4519

This systematic review with meta-analysis examines the rates of cardiovascular adverse events among patients receiving carfilzomib for the treatment of multiple myeloma.

Brief Report

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):374-378. doi:10.1001/jamaoncol.2017.2925

This medical record review evaluates the relation of immune-related adverse events to nivolumab efficacy in non–small-cell lung cancer.

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):379-383. doi:10.1001/jamaoncol.2017.2899

This pooled analysis of 2 randomized clinical trials evaluates the association of DNA mismatch repair status with disease-free survival in patients with stage III colon cancer treated with FOLFOX.

Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):384-388. doi:10.1001/jamaoncol.2017.5029

This analysis of data from an open-label, nonrandomized, multicohort study of patients from the VE-BASKET trial evaluates the efficacy and safety of vemurafenib in the treatment of adults with BRAF V600–mutant Erdheim-Chester disease or Langerhans cell histiocytosis.

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(3):e173420. doi:10.1001/jamaoncol.2017.3420

This study examines the protein expression and DNA alteration for the KRAS, CDKN2A, SMAD4, and TP53 main driver genes to determine their association with patient outcomes after pancreatic cancer surgical resection.

Research Letter

Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):413-414. doi:10.1001/jamaoncol.2017.4658

This study examines the lack of race-adjusted measurements for renal function in eligibility criteria for participation of black men in prostate cancer trials.

Association of Treatment for Hodgkin Lymphoma With Estrogen Receptor Status of Subsequent Breast Cancers

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):414-416. doi:10.1001/jamaoncol.2017.4887

This population-based cohort study examines the association of radiotherapy for Hodgkin lymphoma with risk of ER-positive and ER-negative breast cancers using data from the US National Cancer Institute Surveillance, Epidemiology, and End Results database.

Characteristics of Patients Using Patient Portals in Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):416-418. doi:10.1001/jamaoncol.2017.5257

This study examines the association of accessing electronic oncology patient portal data with patient characteristics and type of portal content.

Review

Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(3):394-400. doi:10.1001/jamaoncol.2017.2009

This review examines the prognostic value of minimal residual disease status in patients with chronic lymphocytic leukemia undergoing treatment with novel therapeutics.

JAMA Oncology Clinical Challenge

A Young Man With Disseminated Intra-abdominal Masses

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(3):401-402. doi:10.1001/jamaoncol.2017.3432

A man in his 20s presented with a 2-month history of vague right upper quadrant abdominal pain, 5-kg weight loss, loss of appetite, and increasing abdominal distension. What is your diagnosis?

Viewpoint

The Hidden Costs of Medical Education and the Impact on Oncology Workforce Diversity

Abstract Full Text
JAMA Oncol. 2018;4(3):289-290. doi:10.1001/jamaoncol.2017.4533

This Viewpoint examines the financial burden of medical school for aspiring oncologists from underrepresented backgrounds and suggests potential programs to help alleviate the financial burden.

The Danger of Applying the ProtecT Trial to Minority Populations

Abstract Full Text
JAMA Oncol. 2018;4(3):291. doi:10.1001/jamaoncol.2017.5452

This Viewpoint examines the generalizability of the results of ProtecT Trial to minority populations.

From the JAMA Network

Not Just Digital Pathology, Intelligent Digital Pathology

Abstract Full Text
JAMA Oncol. 2018;4(3):403-404. doi:10.1001/jamaoncol.2017.5449

This commentary discusses a study in JAMA that compared the ability of machine learning algorithms vs clinical pathologists to detect cancer metastases in whole-slide images of axillary lymph nodes dissected from women with breast cancer.

Editorial

Neoadjuvant Systemic Therapy for Breast Cancer: Searching for More Effectively Curative Therapies

Abstract Full Text
JAMA Oncol. 2018;4(3):293-295. doi:10.1001/jamaoncol.2017.4651
Invited Commentary

Carcinoembryonic Antigen—Still More to Learn From the Real World

Abstract Full Text
JAMA Oncol. 2018;4(3):315-316. doi:10.1001/jamaoncol.2017.4408

Efficacy of Medicaid for Patients With Cancer in California

Abstract Full Text
JAMA Oncol. 2018;4(3):323-325. doi:10.1001/jamaoncol.2017.4356

Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?

Abstract Full Text
JAMA Oncol. 2018;4(3):333-334. doi:10.1001/jamaoncol.2017.4339

Association of Breast Implants With Anaplastic Large-Cell Lymphoma

Abstract Full Text
JAMA Oncol. 2018;4(3):341-342. doi:10.1001/jamaoncol.2017.4467
JAMA Oncology Patient Page

Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):431. doi:10.1001/jamaoncol.2017.4000
Cancer Care Chronicles

History of Lymphoma

Abstract Full Text
JAMA Oncol. 2018;4(3):292. doi:10.1001/jamaoncol.2017.2962
Poetry and Oncology

Faith Healer

Abstract Full Text
JAMA Oncol. 2018;4(3):301. doi:10.1001/jamaoncol.2017.2706
Comment & Response

Difficulties in Defining and Measuring Cancer-Related Fatigue

Abstract Full Text
JAMA Oncol. 2018;4(3):418-419. doi:10.1001/jamaoncol.2017.3355

Difficulties in Defining and Measuring Cancer-Related Fatigue—Reply

Abstract Full Text
JAMA Oncol. 2018;4(3):419-420. doi:10.1001/jamaoncol.2017.3358

All Thiopurines Are Equal but Some Thiopurines Are More Equal Than Others

Abstract Full Text
JAMA Oncol. 2018;4(3):420. doi:10.1001/jamaoncol.2017.0740

All Thiopurines Are Equal But Some Thiopurines Are More Equal Than Others—Reply

Abstract Full Text
JAMA Oncol. 2018;4(3):420-421. doi:10.1001/jamaoncol.2017.3369

Brain Metastases in Lung Cancer With Targetable Mutations: Should We Allow Targeted Treatment in Prognostic Indices?

Abstract Full Text
JAMA Oncol. 2018;4(3):421-422. doi:10.1001/jamaoncol.2016.7022

Brain Metastases in Lung Cancer With Targetable Mutations—Reply

Abstract Full Text
JAMA Oncol. 2018;4(3):422-423. doi:10.1001/jamaoncol.2017.3375

Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?

Abstract Full Text
JAMA Oncol. 2018;4(3):423. doi:10.1001/jamaoncol.2017.3349

Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?—Reply

Abstract Full Text
JAMA Oncol. 2018;4(3):423-424. doi:10.1001/jamaoncol.2017.3352

Issues of Awareness Related to Human Papillomavirus Infection Positivity Among US Adult Men

Abstract Full Text
JAMA Oncol. 2018;4(3):424. doi:10.1001/jamaoncol.2017.0490

Issues of Awareness Related to Human Papillomavirus Infection Positivity Among US Adult Men—Reply

Abstract Full Text
JAMA Oncol. 2018;4(3):424-425. doi:10.1001/jamaoncol.2017.3413

Health Behavioral Models to Find Reasons for Low Rates of Lung Cancer Screening by Low-Dose Computed Tomography

Abstract Full Text
JAMA Oncol. 2018;4(3):425. doi:10.1001/jamaoncol.2017.0493
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):283. doi:10.1001/jamaoncol.2017.3210
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(3):275. doi:10.1001/jamaoncol.2017.3209
×